Predicting the Risk of Ischemic Stroke in Patients Treated with Novel Oral Anticoagulants: A Machine Learning Approach

被引:1
|
作者
Kostev, Karel [1 ]
Wu, Tong [2 ]
Wang, Yue [2 ]
Chaudhuri, Kal [3 ]
Reeve, Russel [4 ]
Tanislav, Christian [5 ]
机构
[1] IQVIA, Epidemiol, Frankfurt, Germany
[2] IQVIA, Adv Analyt, Plymouth, PA USA
[3] IQVIA, Global Consulting, Plymouth, PA USA
[4] IQVIA, Biostat & Decis Sci, Durham, NC USA
[5] Diakonie Hosp Jung Stilling Siegen, Dept Geriatr & Neurol, Siegen, Germany
关键词
Machine learning; Stroke; Prediction analytics; Non-vitamin K antagonist oral anticoagulants; Atrial fibrillation; ATRIAL-FIBRILLATION; CARDIOVASCULAR RISK; MEDICAL-CARE; EPIDEMIOLOGY;
D O I
10.1159/000517512
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: The aim of this cohort study was to estimate the predictors of ischemic stroke in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs) in a large database containing data from general practitioners in Germany using machine learning methods. Methods: This retrospective cohort study included 39,652 patients with a diagnosis of atrial fibrillation (AF) and an initial prescription of NOAC in 1,278 general practices in Germany between January 2011 and December 2018. Of 39,652 patients, 2,310 (5.8%) receive the first stroke or TIA diagnosis during the follow-up time (average follow-up time 2.5 [SD: 1.8] years). Sub-Population Optimization and Modeling Solutions (SOMS) tool was used to identify subgroups at a higher risk of stroke compared to the overall population receiving NOAC based on 37 different variables. Results: Using SOMS, a total of 9 variables were considered important for the stroke prediction. Age had 59.1% of prediction importance, following by ischemic heart diseases (10.6%), urinary tract infections (4.6%), dementia (3.5%), and male sex (3.5%). Further variables with less importance were dizziness (2.2%), dorsalgia (1.5%), shoulder lesions (1.1%), and diabetes mellitus (1.1%). Discussion/Conclusions: The stroke risk in AF patients treated with NOAC could be predicted based on comorbidities like ischemic heart diseases, urinary tract infections, and dementia additionally to age and male sex. Knowing and addressing these factors may help reduce the risk of stroke in this patient population.
引用
收藏
页码:387 / 392
页数:6
相关论文
共 50 条
  • [41] PHARMACODYNAMICS OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ACUTE PERIOD OF ISCHEMIC STROKE
    Petrov, V., I
    Gerasimenko, A. S.
    Gorbatenko, V. S.
    Shatalova, O., V
    [J]. PHARMACY & PHARMACOLOGY-FARMATSIYA I FARMAKOLOGIYA, 2020, 8 (04): : 222 - 232
  • [42] Assessment of a bleeding risk index in patients treated with oral anticoagulants
    vanderMeer, FJM
    Vandenbroucke, JP
    Briet, E
    Rosendaal, FR
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 53 - 53
  • [43] Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants
    Stoellberger, Claudia
    Finsterer, Josef
    [J]. NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2014, 48 (02) : 136 - 140
  • [44] Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
    Meinel, Thomas R.
    Wilson, Duncan
    Gensicke, Henrik
    Scheitz, Jan F.
    Ringleb, Peter
    Goganau, Ioana
    Kaesmacher, Johannes
    Bae, Hee-Joon
    Kim, Do Yeon
    Kermer, Pawel
    Suzuki, Kentaro
    Kimura, Kazumi
    Macha, Kosmas
    Koga, Masatoshi
    Wada, Shinishi
    Altersberger, Valerian
    Salerno, Alexander
    Palanikumar, Logesh
    Zini, Andrea
    Forlivesi, Stefano
    Kellert, Lars
    Wischmann, Johannes
    Kristoffersen, Espen
    Beharry, James
    Barber, P. Alan
    Hong, Jae Beom
    Cereda, Carlo
    Schlemm, Eckhard
    Yakushiji, Yusuke
    Poli, Sven
    Leker, Ronen
    Romoli, Michele
    Zedde, Marialuisa
    Curtze, Sami
    Ikenberg, Benno
    Uphaus, Timo
    Giannandrea, David
    Portela, Pere Cardona
    Veltkamp, Roland
    Ranta, Annemarei
    Arnold, Marcel
    Fischer, Urs
    Cha, Jae-Kwan
    Wu, Teddy Y.
    Purrucker, Jan C.
    Seiffge, David J.
    [J]. JAMA NEUROLOGY, 2023, 80 (03) : 233 - 243
  • [45] Risk of ischemic stroke associated with direct oral anticoagulants discontinuation on patients with non-valvular atrial fibrillation
    Thomsen, T. Alvaro
    Guadalupe, J. Mesa
    Huerta, C.
    de Burgos, A.
    Soriano, L. Cea
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
  • [46] Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants
    Deshpande, Chinmay G.
    Kogut, Stephen
    Laforge, Robert
    Willey, Cynthia
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (07) : 1285 - 1292
  • [47] Reduction in the Doses of Direct Oral Anticoagulants and Risk of Ischemic Stroke Events: A Hospital Survey
    Ueda, Aya
    Toki, Shinji
    Kitayama, Chisato
    Akazawa, Manabu
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2020, 43 (07) : 1135 - 1140
  • [48] Novel oral anticoagulants in acute ischemic stroke with non-valvular atrial fibrillation
    Teo, K. C.
    Chan, K. H.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 1110 - 1111
  • [49] Machine-Learning-Derived Model for the Stratification of Cardiovascular risk in Patients with Ischemic Stroke
    Ntaios, George
    Sagris, Dimitrios
    Kallipolitis, Athanasios
    Karagkiozi, Efstathia
    Korompoki, Eleni
    Manios, Efstathios
    Plagianakos, Vasileios
    Vemmos, Konstantinos
    Maglogiannis, Ilias
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2021, 30 (10):
  • [50] Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
    Baruch, Lawrence
    Gage, Brian F.
    Horrow, Jay
    Juul-Moller, Steen
    Labovitz, Arthur
    Persson, Maria
    Zabalgoitia, Miguel
    [J]. STROKE, 2007, 38 (09) : 2459 - 2463